Tricode
NDC Package 60575-414-16
Package Information
Tricode is do not exceed recommended dosage.Adults and children12 years of ageand over:2 teaspoonfuls (10 mL)every 4 to 6 hours,not to exceed 8 teaspoonfuls in a 24 hour periodChildren 6 to under12 years of age:1 teaspoonful (5 mL)every 4 to 6 hours, not to exceed 4 teaspoonfulsin a 24 hour periodChildren under 6years of ageConsult a doctor.A special measuring device should be used to give an accurate dose of this product to children under 6 years of age. Giving a higher dose than recommended by a doctor could result in serious side effects for your child. Marketed by Respa Pharmaceuticals, Inc., this product is identified by NDC 60575-414 and is authorized under FDA application part341.
Identification & Billing
- RxCUI: 1114110 - codeine phosphate 8 MG / guaiFENesin 200 MG / pseudoephedrine HCl 30 MG in 5 mL Oral Solution
- RxCUI: 1114110 - codeine phosphate 1.6 MG/ML / guaifenesin 40 MG/ML / pseudoephedrine hydrochloride 6 MG/ML Oral Solution
- RxCUI: 1114110 - codeine phosphate 8 MG / guaifenesin 200 MG / pseudoephedrine hydrochloride 30 MG per 5 ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 60575 - Respa Pharmaceuticals, Inc.
- 60575-414 - Tricode
- 60575-414-16 - 473 mL in 1 BOTTLE
- 60575-414 - Tricode
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 60575-414-16 identifies a specific commercial package of 473 ml in 1 bottle of Tricode GF, labeled by Respa Pharmaceuticals, Inc.. This product is billed per "ML" milliliter and contains an estimated amount of 473 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Respa Pharmaceuticals, Inc. on June 20, 2011. The current certification is valid through December 31, 2017.
How is this Respa Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 60575041416. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 473 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.